Novel Peptides Block Key Enzyme, Significantly Reducing Inflammation

Phospholipase C-β (PLC-β) enzymes are crucial for cell signaling pathways, regulating processes like cell growth, differentiation, and immune responses. However, their overactivity is strongly implicated in various inflammatory diseases, including chronic pain, autoimmune conditions, and neuroinflammation. Current anti-inflammatory treatments often lack specificity, leading to systemic side effects or incomplete disease management. This study addresses the critical knowledge gap by investigating whether small peptides derived from PLC-β's own autoinhibitory region can specifically inhibit its activity and thereby offer a targeted approach to reduce inflammation.

The study demonstrated that the small peptides effectively inhibited PLC-β enzyme activity in vitro in a dose-dependent manner. XY-peptide-1 showed potent inhibition against PLC-β1 with an IC50 of 95 nM, while XY-peptide-2 was highly effective against PLC-β2 with an IC50 of 120 nM. > In the carrageenan-induced paw edema model, treatment with XY-peptide-1 at 5 mg/kg significantly reduced paw swelling by 48% compared to the vehicle control group (p<0.001) at the 24-hour mark. This anti-inflammatory effect was sustained, showing a 43% reduction at 48 hours and a 37% reduction at 72 hours (p<0.01 for all time points). Furthermore, the peptides decreased the production of key pro-inflammatory cytokines, such as IL-6 and TNF-α, in inflamed tissues by over 60% compared to controls, indicating a robust anti-inflammatory mechanism.